Testagen
ExperimentalKhavinson endocrine bioregulator / researchExperimental
Short peptide sold as a testicular/endocrine bioregulator. Not FDA-approved; not a testosterone secretagogue with modern RCT evidence.
For research use only.
Key Facts
- CAS
- 1026993-38-3
- Molecular Weight (MW)
- 447.44 g/mol
- Half-life
- Not established (limited public PK data; primarily research context)
- Unit
- mg
- Administration Route
- Oral or sublingual (common commercial formats); injectable research use exists by supplier
- Frequency
- Once daily (typical research pattern)
- Last updated
- 8/23/2026
- Targets
- Testicular cells (proposed)
Overview
Short peptide sold as a testicular/endocrine bioregulator. Not FDA-approved; not a testosterone secretagogue with modern RCT evidence.
Protocol
- Dosage Range
- 5-20 mg daily (research context; not clinically established)
- Frequency
- Once daily (typical research pattern)
- Cycle
- 10-30 days common in bioregulator style protocols (research context)
- Administration Route
- Oral or sublingual (common commercial formats); injectable research use exists by supplier
- Reconstitution Guide
- If lyophilized: reconstitute with bacteriostatic water per lab SOP (research only)
Science
Mechanism of Action
Claimed to support Leydig/Sertoli protein synthesis in Khavinson-series papers. Not a substitute for labeled hypogonadism therapy.
Targets
Testicular cells (proposed)
Studies
- Khavinson bioregulatorsโ Journal/year not available
Benefits
Historical endocrine-bioregulator category
Potential Side Effects
- Not characterized
References
- PMID 15587334External link ยท Year โ